Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.
Sidar CopurAlan A SagBaris AfsarPatrick RossignolAdrian CovicMehmet KanbayPublished in: International urology and nephrology (2020)
Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.
Keyphrases
- chronic kidney disease
- end stage renal disease
- insulin resistance
- peritoneal dialysis
- skeletal muscle
- systematic review
- newly diagnosed
- type diabetes
- machine learning
- metabolic syndrome
- adipose tissue
- risk factors
- prognostic factors
- deep learning
- high fat diet
- patient reported outcomes
- body composition
- anti inflammatory
- replacement therapy
- bone loss
- high fat diet induced
- glycemic control